Adma Biologics (ADMA) Net Margin: 2011-2025
Historic Net Margin for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to 27.14%.
- Adma Biologics' Net Margin fell 282.00% to 27.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.37%, marking a year-over-year increase of 2730.00%. This contributed to the annual value of 46.35% for FY2024, which is 5729.00% up from last year.
- Adma Biologics' Net Margin amounted to 27.14% in Q3 2025, which was up 23.06% from 22.05% recorded in Q2 2025.
- Adma Biologics' Net Margin's 5-year high stood at 95.19% during Q4 2024, with a 5-year trough of -114.26% in Q1 2021.
- In the last 3 years, Adma Biologics' Net Margin had a median value of 21.75% in 2024 and averaged 17.46%.
- In the last 5 years, Adma Biologics' Net Margin spiked by 15,346bps in 2021 and then tumbled by 282bps in 2025.
- Quarterly analysis of 5 years shows Adma Biologics' Net Margin stood at -30.01% in 2021, then spiked by 641bps to -23.59% in 2022, then declined by 28bps to -23.88% in 2023, then surged by 11,907bps to 95.19% in 2024, then slumped by 282bps to 27.14% in 2025.
- Its last three reported values are 27.14% in Q3 2025, 22.05% for Q2 2025, and 23.44% during Q1 2025.